Medicine/Health

Hebrew University Autism Researcher Receives Prestigious Grant from the Eagles Autism Foundation

Hebrew University Autism Researcher Receives Prestigious Grant from the Eagles Autism Foundation

21 March, 2023

 

The Hebrew University of Jerusalem Prof. Haitham Amal has received a prestigious research grant from the Philadelphia Eagles Autism Foundation to develop new drugs for the treatment of Autism Spectrum Disorder (ASD).

Read More
Amal is the first researcher outside the U.S. to be awarded the $400,000 Eagles Autism Foundation Grant. He is one of only nine grant recipients selected by a distinguished panel of nationally recognized U.S. researchers.

“I am excited and honored to receive this significant award as the first global recipient,” says Amal, a professor at the Hebrew University School of Pharmacy, Institute for Drug Research, Faculty of Medicine. “This grant will enhance our research initiatives to develop ASD therapeutics that will help millions of children and families around the world.”

The grant is funding Amal’s groundbreaking research on the role of nitric oxide (NO) in ASD pathology. Amal published the first paper linking nitric oxide with ASD, a key step toward identifying a drug target for the disorder. NO is a multifunctional signaling molecule and a neurotransmitter that plays an important role in physiological and pathophysiological processes.

 

Recently, Amal co-founded and is Chief Scientific Officer at Point6 Bio Ltd, a computational biology company for the diagnosis and treatment of ASD. He is also partnering with a NASDAQ-traded U.S. pharmaceutical company to research and develop ASD drugs.

In his Laboratory for Neuromics, Cell Signaling, and Translational Medicine, Amal leads a group of scientists whose goal is to discover therapeutics and biomarkers for ASD, Alzheimer’s, other brain disorders, and diseases.

He has received many awards including the Wolf Foundation’s prestigious Krill Prize, the Prusiner-Abramsky Research Award in Clinical and Basic Neuroscience, the Kaye Innovation Award, the Golda Meir Lectureship Award, and the Brettle Center for Research Award. Among the numerous grants he has received include funding from the U.S. Department of Defense and the Israel Science Foundation. Prof. Amal was listed among the 40 under 40 most promising people in Israel by The Marker Magazine, a major business publication.

Prior to joining Hebrew University, Amal was a Senior Postdoctoral Fellow at MIT and an affiliate in the Stanley Center for Psychiatric Research at the MIT Broad Institute and Harvard. In 2015, he received his Ph.D. from the Technion-Israel Institute of Technology in Nanotechnology and Chemical Engineering. Amal received his M.S. in Pharmacology at Tel Aviv University in 2009 and a B.S. in Pharmacy from Hebrew University in 2007.

 

 

Read Less
Researchers Find Seven New Spider Species in Caves in Israel

Researchers Find Seven New Spider Species in Caves in Israel

10 February, 2023

Seven new species of funnel web spiders (Agelenidae, Tegenaria), unique to caves in Israel, have been discovered and are detailed in a new study conducted by researchers from the Hebrew University of Jerusalem and the University of Madison-Wisconsin.

Read More
The unique, isolated conditions in cave habitats lead to a process of convergent evolution, causing the development of exceptional adaptations to life in the dark, such as blindness, loss of pigments, and sensory organ enlargement.

These species join a large number of invertebrates recently found in Israeli caves that are new to science. The study was recently published in the Molecular Phylogenetics and Evolution journal and has extensive scientific implications for uncovering the evolution of speciation in caves and the historical, geographic, and climatic processes that occurred in Israel.

Doctoral student Shlomi Aharon led the study under the guidance of Dr. Efrat Gavish-Regev, from the Hebrew University National Natural History Collections and Prof. Dror Hawlena from the Department of Ecology, Evolution, and Behavior.

“In many cases, these adaptations will lead to the creation of new species, whose distribution is geographically limited in areas with unique ecological conditions, such as a single cave or a system of connected caves,” Aharon says. “In this study, we sought to understand the evolutionary relationships between funnel web spiders with normal eyes that are found at the cave entrance, with those that are further in the cave and are pigmentless, eye-reduced, and even completely blind.”

In the study, the researchers collected the spiders by hand and then conducted a series of microscopic examinations, recorded the morphology, and extracted DNA from each to compare them to sequences of known species of the same genus that exist in GenBank.

“Among the spiders we found, five were unique to different caves, and the two other species were found in several caves in the Galilee and in caves situated at the Ofra karst field, which is now under threat from planned construction,” says Dr. Gavish-Regev. “One of the surprising findings in the study shows that the new species are evolutionarily closer to species from caves in Mediterranean areas in southern Europe than to species living in close proximity to them at cave entrances in Israel.”

Five of the new species described had reduced eyes, while the other two were completely blind. The researchers suggest that the new species developed adaptations to life in underground habitats and speciated in caves, after or simultaneously with the extinction of the ancestor species from which they evolved, which lived outside caves and became extinct due to historical regional climate changes.

“We are currently witnessing the effects of climate change on many habitats, which obliges us to consider, maintain, and promote programs that include the preservation of underground habitats – many of which are at immediate risk,” concludes Professor Hawlena. “We must protect Israel’s unique nature, preserve its underground systems for the future, and further explore the processes that created these systems in the country.”

Read Less
Researchers at Hebrew University and University of Kentucky Receive $1 Million Grant to Study Human Brain Complexity

Researchers at Hebrew University and University of Kentucky Receive $1 Million Grant to Study Human Brain Complexity

8 February, 2023

The Hebrew University of Jerusalem (HU) and University of Kentucky researchers are exploring whether a new type of protein substantially increases the molecular complexity in the brain and improves its function. This may have implications for the study of neurological diseases such as schizophrenia, epilepsy, and autism.

Read More
The researchers recently received a $1 million joint grant from the American National Science Foundation (NSF) and the United States-Israel Binational Science Foundation (BSF) to study new aspects of RNA biology.

The team of researchers, led by Prof. Ruth Sperling of the Hebrew University Alexander Silberman Institute of Life Sciences, together with Prof. Stephen Stamm from the School of Medicine in Lexington, Kentucky, hypothesize that a new type of primate-specific proteins, translated from molecules of circular RNA, improves the brain’s function in relation to other organisms with a similar number of genes.

RNA is the mediator in turning instructions encoded in DNA into cellular proteins. As part of the process, the RNA is heavily modified: some pieces are cut out and the remaining parts are put back together, to assemble a new line of RNA – which fundamentally changes their composition. Sometimes, these parts form in circles, creating circular RNA.

Circular RNAs are mostly found in the brain and their formation is promoted by genomic elements specific to humans and other primates, called Alu-elements. The human genome consists of about 11% Alu-elements and their expansion in primates correlates with brain complexity.

“For the first time, the team of researchers will focus on new biological aspects of the circular RNA molecules, with the aim of revealing why humans have a stronger and more complex brain than other organisms with a similar number of genes,” Stamm says.

Prof. Sperling, a world-renowned expert in RNA processing, is seeking to understand how circular RNA is created by the splicing machinery in cells, to analyze when this occurs and how it is regulated in the brain.

According to Sperling, “If we do find that we have new proteins, this opens up a completely new research field with essential functions for the human brain.” Such a discovery may have wide implications, for example, on the detection of genetic materials correlated with schizophrenia, epilepsy, autism, or neurological disease.”

The hypothesis is that the new proteins, translated from these specific circular RNAs, substantially increase molecular complexity, which improves brain functions. “Do circular RNAs code for proteins? Do these proteins function? Can they be found in the brain? This is what we are analyzing. It has never been looked at,” Stamm says.

As part of the three-year project, there will be annual two-week RNA biology courses held in the summer at Hebrew University in Jerusalem led by Stamm and Sperling. Students from both universities will have theoretical lectures and do hands-on experiments during the course.

Research reported in this publication was supported by the National Science Foundation under Award Number 2221921, and United States-Israel Binational Science Foundation under Award Number 2022602.

Read Less
vv

Dr. Karma Ben-Johanan Receives the Dan David Prize for her Contributions to Comparative Religion Research

2 February, 2023

 

Read More

 

The prestigious Dan David Prize for the Study of History was awarded to nine scholars from around the world. The prize amounts to $300,000USD and is awarded for the second year in its new format by the Dan David Foundation at Tel Aviv University.

Among the winners of the distinguished Prize for 2023 is Dr. Karma Ben Johanan of the החוג למדע הדתות באוניברסיטה העברית - The Department of Comparative Religion whose groundbreaking research in the field of relations between religions advances historical research and sheds light on the past. She is the first Israeli woman to receive the prize since it was founded in 2001.

Dr. Ben-Johanan is a scholar of contemporary theology and Jewish-Christian relations. Her dissertation focused on mutual theological views of Catholic and Orthodox Jews in recent decades. She was awarded the Dan David Prize for her research on the relationships between different religious traditions, the Catholic Church's reconciliation initiative with Jews after the Second Vatican Council and the reactions of Orthodox Jewish thinkers and rabbis to these developments. This May, a special ceremony will be held in Tel Aviv where the Dan David Awards will be presented to the nine new winners.

The Dan David Prize was first awarded in 2001 by the late entrepreneur and philanthropist Dan David, with the aim of rewarding innovative and interdisciplinary research work that contributed to humanity. Starting in 2021, the award has been relaunched and focuses on significant and groundbreaking historical research. Today, the prize rewards leading historians, with the aim of helping them realize their research potential at a time when support for the humanities is diminishing.

Photo: Avigail Piperno-Beer

 

 

Read Less
The Lancet Publishes Hebrew University Professor's Letter On Israel's Cancellation of its Sweetened Beverage Tax Due to Health Concerns

The Lancet Publishes Hebrew University Professor's Letter On Israel's Cancellation of its Sweetened Beverage Tax Due to Health Concerns

1 February, 2023

 

Co-Authors Include Renowned Health Scholars and Members of the World Federation of Public Health Associations

 

Read More

 

Referring to the cancellation of Israel's sweetened beverage tax, as "a grievous blow to public health," Hebrew University Prof. Aron Troen, and a renowned worldwide group of senior health scholars have published a letter in The Lancet prestigious medical journal seeking to overturn the harmful, hasty, and costly decision. See attached for text of letter.

Approximately 64 percent of adults in Israel are overweight, defined as a body mass index over 25 according to the World Health Organization (WHO). Childhood obesity is on the rise, and its poor populations carry the greatest burden of associated chronic disease, like diabetes. The direct and indirect costs of obesity to Israeli society are estimated at 20 billion NIS ($5.8 Billion) annually.

"Since its introduction a year ago, the tax has reduced the consumption of sweetened drinks by about 10%," says Troen who is a member of the World Federation of Public Health Associations. “The fact that world health leaders have responded shows what an important issue we’re dealing with. Canceling the tax is irresponsible, an act of public health malpractice, and an outrage.”

In the letter, the authors state that, "Revoking the tax will undoubtedly harm lives and increase the direct and indirect economic costs to Israel's health system and economy, both in the short term and long term. More broadly, this act undermines hard won progress made elsewhere around the world. It is a serious setback for evidence-based public health policy and will be celebrated by vested interests who promote their products and disregard the need for policies that uphold the public's health and welfare. This decision will be seen as prioritizing sectorial political interests over incontrovertible scientific evidence and public health best practice."

The scholars conclude the letter by, "calling on the Government of Israel to reconsider and retract this ill-conceived and hasty decision. Instead, let the revenue from the soda tax be used to combat chronic diseases including obesity, as well as promote nutrition security by increasing economic access to healthy diets, narrowing health disparities, improving the health and welfare of all Israeli citizens, and setting an example for world health leadership."

Other co-authors include Darius Mozaffarian, Dean for Policy at Tufts University's Friedman School of Nutrition Science who co-chairs the task force that informed the White House Conference on Hunger and Nutritional Security, Barry Popkin, a world-renowned health economist, and Hagai Levin from the Hebrew University School of Public Health and chair of the Israeli Association of Public Health Physicians.

About the Hebrew University of Jerusalem

The Hebrew University of Jerusalem is Israel's leading academic and research institution. Serving some 24,000 students from 80 countries, it produces a third of Israel’s civilian research and is ranked 12th worldwide in biotechnology patent filings and commercial development. Faculty and alumni of the Hebrew University have won eight Nobel Prizes and a Fields Medal. For more information about the Hebrew University, please visit http://new.huji.ac.il/en.

About American Friends of the Hebrew University

American Friends of the Hebrew University (AFHU) is a national, not-for-profit organization based in the United States. AFHU is headquartered in New York and has seven regional offices working in close partnership with the Hebrew University of Jerusalem. AFHU provides supporters, Hebrew University alumni, and the public with stimulating programs and events, and organizes missions to Israel. The organization’s activities support scholarly and scientific achievement at HU, create scholarships, fund new facilities, and assist the university’s efforts to recruit outstanding new faculty.

For more information, please visit http://www.afhu.org.

Follow us on: Facebook | Linkedin | Twitter  | Instagram | YouTub

 

 

Read Less
hh

Hebrew University Researchers Develop Cancer Nanotherapies Effective in Tumor Eradication

13 January, 2023

An international team from the Hebrew University of Jerusalem (HU) and the Instituto de Microelectronica de Barcelona developed metal iron-based biodegradable magnetoplasmonic nanocapsules (MAPSULES) to eradicate tumors via remote-controlled local delivery of chemotherapy at ultralow drug concentrations.

Read More

The findings of this study were published in ACS Nano Journal and featured on the cover of the latest issue, demonstrated positive therapeutic effects of MAPSULES in biological models carrying human breast tumors. The MAPSULES also boost drug therapeutic action and minimize damage to surrounding tissues.

This study, led by Arnon Fluksman, a Ph.D. student in Prof. Ofra Benny’s laboratory at the Hebrew University Faculty of Medicine’s School of Pharmacy, and  Dr. Borja Sepulveda and his team at the Instituto de Microelectronica de Barcelona, fabricated and evaluated MAPSULES in various cancer cell models.

“With over 18 million cancer cases worldwide in 2020, scientists and medical practitioners have grappled with advancing local drug delivery methods to improve treatment outcomes,” says Fluksman. Despite the promise of overcoming chemotherapy side effects, nanotherapies have been unable to meet expectations due to the low nanoparticle concentration that ultimately reaches the solid tumor. Our unique method enables us to remotely control the molecules with the help of a magnet, deliver drugs to the precise location of the tumor, and control drug release rates.”

Results also showed that laser irradiation of MAPSULES could increase therapeutic impact by generating heat locally in the tumor site. These findings introduce the first design of a full nano-scale carrier containing large doses of chemotherapeutics with a thin external metal coating, effectively delivering chemotherapy to a solid tumor site.

“Creating an ‘Iron Dome’ of sorts for cancer, MAPSULES not only kill cancerous cells but also protect the patient from unnecessary damage to healthy tissue, thus augmenting cancer treatment outcomes,” said Prof. Benny. “With our discovery of MAPSULES’s efficacy, we can advance our solutions and offer a wide range of materials that can be manipulated and activated remotely to support a wide variety of therapies for diseases beyond cancer.”

 

Read Less
The Philip Morris tobacco company spent NIS 3 million on advertising to increase its profits and drive addiction to smoking in the Haredi public

The Philip Morris tobacco company spent NIS 3 million on advertising to increase its profits and drive addiction to smoking in the Haredi public

30 November, 2022

A Hebrew University research study finds that 87% of cigarette advertisements targeting specific population groups were aimed at Haredi society, exploiting loopholes in the Prohibition of Advertising and Restriction of Marketing of Tobacco and Smoking Products Law.

A new research study, conducted by doctoral student Amal Khayat and led by Dr. Yael Bar-Zeev and researchers at the Hebrew University’s Braun School of Public Health and Community Medicine, shows that one of the world’s largest tobacco companies exploited loopholes in the law against advertising smoking products in Israel, and specifically targeted the Haredi population in Israel. The study findings, which were recently published in the academic journal Tobacco Control, reveal a series of advertising strategies that focused on the population group with the lowest rates of smoking in Israel.

Read More

A new research study, conducted by doctoral student Amal Khayat and led by Dr. Yael Bar-Zeev and researchers at the Hebrew University’s Braun School of Public Health and Community Medicine, shows that one of the world’s largest tobacco companies exploited loopholes in the law against advertising smoking products in Israel, and specifically targeted the Haredi population in Israel. The study findings, which were recently published in the academic journal Tobacco Control, reveal a series of advertising strategies that focused on the population group with the lowest rates of smoking in Israel.

Analyzing the marketing data of Philip Morris International, the researchers examined the differences in advertising expenditure over a four-year period between advertising focused on different major population groups in Israel—the general population, the Haredi public, Arab speakers, and Russian speakers. “We conducted a comparison among the advertising expenditures for all Philip Morris cigarette brands and the IQOS brand (a heated tobacco stick that entered the local market in December 2016), in light of regulatory changes that restricted the advertising of tobacco products,” explains Khayat.

While the restriction on advertising tobacco products led to a significant reduction in the company’s marketing expenditures, the study shows that the company exploited legal loopholes in order to subvert the law’s goals and increase its own profits as much as possible. “Even after the law came into effect, the company continued to spend almost NIS 3 million on advertising, with a focus on the printed press,” explains Dr. Bar-Zeev. “While the law restricted print advertising to one advert in each newspaper, 40% of the IQOS adverts placed were giant, two-page adverts, which effectively doubled the product’s advertising space, while still being considered a single advert as allowed by the letter of the law.”

Another strategy used by Philip Morris was adding a QR code to the advert, which readers could scan and then view additional content, beyond that contained in the advert permitted in the newspaper. Furthermore, the adverts featured people smoking IQOS devices in closed public spaces, despite the fact that the law forbids

 

the use of any tobacco products in such areas. According to the researchers, adverts like this give the impression that such behavior is legally permitted, and exploits the innocence of the majority of consumers, who are not aware of these distinctions.

The study further finds that before the law came into effect, Philip Morris significantly increased its advertising to all the population groups examined, with a particular focus on the Haredi population, which had the lowest rates of smoking in Israel. “Our data shows that since the introduction of the IQOS e-cigarettes, 216 targeted adverts were published, of which 55% were for the Haredi public, 6% for the Arab public, and the rest for the Russian-speaking public,” says Dr. Bar-Zeev. Similarly, for regular cigarette brands, 87% of advertisements were targeted at the Haredi population—a surprising finding given the company’s repeated claims that it is only interested in marketing its products to existing smokers. Dr. Bar-Zeev adds: “We expected that the company would focus on populations with the highest rates of smoking in Israel—men in the Arab sector—and not on the population which has hardly any smokers.”

In the wake of the study findings, the previous Knesset assembly decided to cancel the exception for advertising in the printed press, but deferred implementation of this step for seven years. In discussions, a series of additional restrictions were decided upon for this interim period, including prohibitions on the use of coupons, on the use of QR codes, and on featuring cigarette packs which do not carry the mandatory plain packaging in adverts in the printed press. However, Dr. Bar-Zeev concludes that this is merely “a drop in the ocean,” as the study has proved that the tobacco companies bypass such restrictions, and find creative ways to continue marketing their products and getting a new generation of smokers addicted to them. The researchers argue that only a full and immediate ban on all forms of advertising, combined with strict enforcement of the law, can stop this happening.

 

The academic articles presenting the study findings are available here:

http://dx.doi.org/10.1136/tc-2022-057585

http://dx.doi.org/10.1136/tc-2022-057671

 

 

Read Less
Breakthrough in Antibiotic Safety:  Bionic Technology Blends Sensors and Human Tissue to Create Smart “Kidney-Chip”

Breakthrough in Antibiotic Safety: Bionic Technology Blends Sensors and Human Tissue to Create Smart “Kidney-Chip”

23 November, 2022

Antibiotic resistance is a growing public health concern with global implications. Antibiotic-resistant infection affects over 2.8 million individuals each year in the United States alone, resulting in more than 35,000 annual deaths. New resistance mechanisms constantly emerge and spread globally, threatening our ability to treat common infectious diseases, such as pneumonia, tuberculosis, and sepsis.

Read More
Gentamicin is a commonly-used antibiotic, considered an essential medicine by the World Health Organization (WHO). Antibiotics of this kind (aminoglycosides) cause kidney damage in up to 25% of hospitalized patients. This is a major problem for more than 37 million Americans estimated to suffer from chronic kidney disease, according to the Center for Disease Control (CDC). In fact, the American Federal Drug Administration (FDA) considers the development of antibiotics for patients with chronic kidney disease to be a national priority.

A group of researchers, led by Professor Yaakov Nahmias, Director of the Grass Center for Bioengineering at the Hebrew University of Jerusalem, and founder of the biotechnology startup Tissue Dynamics, found a new mechanism of antibiotics-induced kidney damage, never identified before. “Most work in the drug development field is being carried out in mice”, said Nahmias, “and the mechanism we found is human-specific”.

The academic team partnered with Tissue Dynamics to develop a bionic micro-kidney in which electrooptical sensors—roughly half the width of a single human hair--are embedded in human kidney tissue. The chip emulates normal human physiology, producing far more accurate behavior than small animals.  The sensors allowed the Hebrew University team to measure glucose accumulation in the micro-kidneys, that led to rapid lipid accumulation and kidney damage. “Humans make lipids from sugar, while rodents mostly make lipids from dietary lipids”, explained Nahmias. Blocking glucose reabsorption in the kidney using the diabetic drug empagliflozin blocked the antibiotic toxicity.

“This is a dramatic demonstration that bionic technology, which blends sensors with human tissue, could rapidly propel drug development forward”, shared Nahmias, whose company Tissue Dynamics was recently selected as one of the top 5 organ-on-chip companies in the world.

Read Less